SCHEMBL2932221

SCHEMBL2932221

N#Cc1cnccc1-c1cc(C#N)c(Cl)nc1-c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.40
CNR1 P21554 5/20 0.39
CNR2 P34972 4/20 0.39
CYP11B2 P19099 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP11B1 P15538 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
CYP3A4 P08684 1/20 0.39
KDM4E B2RXH2 2/20 0.38
KDM1A O60341 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930459 0.86 RPS6KA3 (0.43) RPS6KA3CNR1CYP11B2CYP1A2CYP2C9
SCHEMBL2932218 0.86 CNR1 (0.49) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL2926256 0.78 KDM4E (0.49) CYP1A2CYP2C9CYP2C19MAPK13GCGR
SCHEMBL6626450 0.78 RPS6KA3 (0.47) RPS6KA3CYP11B2CYP1A2CYP11B1MAPK13
SCHEMBL8093828 0.75 CNR1 (0.52) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL8087025 0.73 PTGS2 (0.54)
SCHEMBL8776895 0.73 PTGS2 (0.47) MAPK13MAPK12MAPK11MAPK14
SCHEMBL8776847 0.72 CNR1 (0.52) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL2935037 0.72 MAPK14 (0.47) CNR1CNR2CYP1A2CYP2C9CYP2C19
SCHEMBL19835709 0.72 CNR1 (0.55) CNR1CNR2CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP disclosed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 RPS6KA3 337/4885CNR1 2230/4885CNR2 2514/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 RPS6KA3 155/4885CNR1 3068/4885CNR2 3458/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 RPS6KA3 155/4885CNR1 3068/4885CNR2 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.